Virchow Biotech Private Limited

Virchow Biotech Private Limited (VBPL) is a prominent biopharmaceutical company headquartered in Hyderabad, India. Established on April 4, 2001, the company specializes in the development and manufacturing of high-quality biogenerics, pharmaceuticals, medical devices, and active pharmaceutical ingredients (APIs). As part of the Virchow Group, VBPL leverages over four decades of operational experience, with the group serving over 100 countries and employing approximately 3,500 professionals.

The company is registered under the Corporate Identification Number (CIN) U24210TG2001PTC036520. Its authorized capital stands at ₹205 million, with a paid-up capital of ₹170.33 million. As of April 7, 2024, VBPL employs approximately 1,048 individuals. The company's official website is virchowbiotech.com.

VBPL operates state-of-the-art manufacturing facilities in Hyderabad, India, adhering to stringent quality standards. The facilities are certified by the World Health Organization's Good Manufacturing Practices (WHO-GMP) and ISO 13485:2016, ensuring compliance with international quality benchmarks. These facilities are equipped with advanced clean-room environments and fill-finish lines, enabling the production of a diverse range of pharmaceutical products, including biogenerics, recombinant proteins, and medical devices.

The leadership team at VBPL is spearheaded by Managing Director Hemanth Nandigala, who has been instrumental in the company's growth and strategic direction. The board of directors includes Narayana Reddy Mundla, Venkata Reddy Nandigala, and Murali Krishna Reddy Tummuru. While specific details about the Chief Financial Officer (CFO) and other key executives are not publicly disclosed, the company's leadership is known for its commitment to innovation and quality in the biopharmaceutical sector.

VBPL has established a significant presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company holds approvals from the U.S. Food and Drug Administration (FDA) and the World Health Organization's Good Manufacturing Practices (WHO-GMP), facilitating access to these markets. Additionally, VBPL has received approvals from regulatory bodies in Brazil (ANVISA GMP), Colombia (INVIMA GMP), and Canada (NNHPD), further expanding its global footprint.

VBPL has made strategic inroads into emerging markets across Africa, Latin America, and Southeast Asia. The company's WHO-GMP certification enhances its ability to meet international quality standards, facilitating market access in these regions. By obtaining approvals from regulatory authorities in countries such as Brazil, Colombia, and Canada, VBPL demonstrates its commitment to expanding its global reach and serving diverse patient populations.

VBPL's geographic strategy reflects a balanced approach to market diversification and risk management. The company's presence in both developed and emerging markets allows it to leverage growth opportunities while mitigating potential risks associated with over-reliance on a single region. By obtaining approvals from various international regulatory bodies, VBPL demonstrates its commitment to meeting global quality standards and expanding its global footprint.

VBPL's manufacturing facilities are registered with the U.S. Food and Drug Administration (FDA), indicating compliance with U.S. regulatory standards. The company has received FDA approvals for its products, facilitating market access in the United States. Specific details regarding approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed. However, the FDA registration and approvals underscore VBPL's commitment to maintaining high-quality manufacturing practices.

VBPL holds certifications from the World Health Organization's Good Manufacturing Practices (WHO-GMP) and the European Union's Good Manufacturing Practices (EU GMP), demonstrating compliance with international quality standards. These certifications are crucial for market access in various countries and reflect the company's dedication to producing high-quality pharmaceutical products.

In India, VBPL operates under the regulatory oversight of the Central Drugs Standard Control Organisation (CDSCO). The company holds manufacturing licenses and approvals from state drug controllers, ensuring compliance with national regulations. Additionally, VBPL has obtained export No Objection Certificates (NOCs) from the Directorate General of Foreign Trade (DGFT), facilitating international trade.

As of March 28, 2026, there are no publicly available records indicating any Form 483 observations, warning letters, or import alerts issued to VBPL by regulatory authorities. This absence suggests that the company maintains a strong compliance record with regulatory standards.

In the biopharmaceutical sector, VBPL faces competition from both domestic and international companies offering similar products. While specific market share data is not publicly disclosed, VBPL's certifications from WHO-GMP, EU GMP, and FDA, along with its diverse product portfolio, position it as a competitive player in the global market.

VBPL's key differentiators include its extensive experience in biopharmaceuticals, commitment to innovation, and adherence to international quality standards. The company's specialization in biogenerics, recombinant proteins, and medical devices, coupled with its global certifications, underscores its competitive advantages in the industry.

VBPL's strategic direction focuses on the development and commercialization of biogenerics, recombinant proteins, and medical devices. The company's adherence to international quality standards and its global certifications position it well for future growth and expansion in the biopharmaceutical sector.

VBPL has demonstrated a consistent track record in manufacturing and exporting pharmaceutical products. The company's adherence to international quality standards, as evidenced by its certifications from WHO-GMP, EU GMP, and FDA, indicates reliability and commitment to quality.

Importers should verify the following certifications to ensure product quality and regulatory compliance:

• FDA Approval: Confirm the company's registration and product approvals with the U.S. Food and Drug Administration.

• WHO-GMP Certification: Ensure the company holds certification from the World Health Organization's Good Manufacturing Practices.

• EU GMP Certification: Verify the company's compliance with the European Union's Good Manufacturing Practices.

• ISO 13485:2016 Certification: Check for certification indicating compliance with international standards for medical devices.

These certifications can typically be verified through the respective regulatory bodies' official websites or by contacting the company directly.

When considering VBPL as a supplier, importers should undertake the following verification steps:

• Regulatory Compliance: Confirm the company's certifications and approvals from relevant regulatory authorities.

• Product Quality: Review product quality reports and certifications to ensure compliance with international standards.

• Financial Stability: Assess the company's financial health through available financial statements and reports.

• Supply Chain Reliability: Evaluate the company's track record in meeting delivery schedules and handling logistics.

Red flags to watch for include discrepancies in certification details, unresolved regulatory issues, and inconsistent product quality reports. Recommended pre-order checks involve requesting samples for quality assessment and verifying the company's compliance history with regulatory bodies.